Findings from the 2015 Lymphoma Research Foundation scientific symposium on adolescent/young adult (AYA) lymphomas have been published int he influential journal Blood Advances. The paper, “Adolescent and Young Adult Lymphoma: Collaborative Efforts at Understanding Biology and Optimizing Care,” reviews lymphoma…
Lymphoma Research Foundation’s Premier Light it Red for Lymphoma Initiative Expected to Reach Millions During Blood Cancer Awareness Month New York, NY (August 23, 2017) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to…
New York, NY (August 3, 2017) – New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (Imbruvica ®) to treat patients with chronic graft versus host disease (cGVHD) who have…
The Nation’s Premier Lymphoma-Specific Research Organization Also Adds Four Experts to Industry Leading SAB New York, NY (July 1, 2017) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and…
New York, NY (June 5, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of subcutaneous rituximab (Rituxan ®) to treat patients with previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL),…
Local wine and food patrons gather in support of the Lymphoma Research Foundation’s mission Chicago, IL (June 8, 2017) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving…
Applications for 2018 research grants are now open and will be accepted until September The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive…
New York, NY (March 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of pembrolizumab (KEYTRUDA ®) to treat patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three…
By: Ann LaCasce, MD and Sonali M. Smith, MD The last decade has seen a number of exciting developments in lymphoma research, with new therapies, improved treatment strategies, and a more developed understanding of lymphoma biology improving patient treatment and…